This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Academia Sinica, Pharmigene, Inc.. Active years: 2011-2012.
Company Filing History:
2 out of 726 
2 out of 2 Years Active: 2011-2012
Title: Chi-Feng Chang: Innovator in Genetic Risk Assessment
Introduction
Chi-Feng Chang, an accomplished inventor based in Taipei, Taiwan, has made significant contributions to the field of genetics through his innovative research and patent work. With a total of two patents to his name, Chang's work focuses on understanding genetic markers that can indicate the risk of adverse drug reactions in patients.
Latest Patents
One of Chi-Feng Chang's latest patents revolves around the identification of HLA alleles linked to adverse drug reactions. The invention describes a method for determining the presence of specific HLA alleles, such as HLA-B*1502 and HLA-B*5801, along with a corresponding kit designed for this purpose. This patent also highlights a method for assessing whether individuals are at risk for developing severe adverse reactions, which may include conditions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, based on the presence or absence of genetic markers like HLA-B*1502, HLA-B*5801, or HLA-B*4601.
Career Highlights
Chi-Feng Chang has demonstrated exceptional expertise in his field, having worked at renowned organizations such as Academia Sinica and Pharmigene, Inc. His work in these institutions has been pivotal in advancing research related to pharmacogenomics and patient safety.
Collaborations
Throughout his career, Chang has collaborated with notable colleagues, including Yuan-Tsong Chen and Shuen-Iu Hung. These collaborative efforts have enabled him to enhance his research outcomes and contribute significantly to the scientific community.
Conclusion
Chi-Feng Chang represents the spirit of innovation in genetic research and the critical understanding of drug safety. His inventions not only advance scientific knowledge but also offer practical solutions for improving patient care. As he continues his work, his contributions are expected to have a lasting impact on the field of pharmacogenomics and personalized medicine.